Antibiotics
Bacterial infections, including pneumonia, neonatal sepsis and meningitis are one of the world’s leading causes of morbidity and mortality among children younger than five years of age.
An estimated 3 million cases of neonatal sepsis and 500,000 associated deaths occur each year. Antimicrobial resistance (AMR) further exacerbates this burden; globally, more than more than 214 000 infants (under one year of age) die because of antimicrobial resistance annually, with up to 40% of all bacterial infections among babies showing drug resistance.
Despite the growing burden, very few antibiotics are developed specifically for children and neonates. WHO's 2025 antibacterial pipeline analysis identified that of 16 new antibacterial agents authored in the last decade, only one includes a license for neonates.
Neonates and infants are particularly vulnerable because of their immature immune systems, higher risk of infectious disease and limited treatments options available when they do get sick with antimicrobial-resistant infections. Inadequate access to safe water and sanitation make resource-constrained settings, particularly vulnerable to infections with antimicrobial-resistant infections. Currently, neonatal and paediatric drug development and evidence generation occurs many years after adult approval, delaying access to appropriate therapies for these life-threatening infections.
To address these gaps, WHO conducted the Paediatric Drug Optimization for Antibiotics (PADO) exercise in 2023 to identify priority products for development. This work informed the development of Target Product Profiles (TPPs) for priority oral paediatric antibiotics and new antibacterial agents, published in 2026, as well as a WHO Prequalification Expression of Interest (EOI) to stimulate the development of age-appropriate formulations. In parallel, WHO convened multidisciplinary stakeholder consultations in 2026 to advance and optimize antibiotic development for neonates and children. Building on these efforts, WHO is also leading a new initiative to develop global clinical guidance for the development of novel antibiotics in paediatric populations, with the aim of strengthening evidence generation, informing regulatory and policy decision-making, and accelerating access to priority antibiotics for children of all ages, including neonates.
Portfolio products
Portfolio Updates |
|---|
|
PADO report
Contact
Email: gigantev@who.int
Related publications
Target product profiles for new antibacterial agents
This World Health Organization (WHO) report presents target product profiles (TPPs) for new antibacterial agents for therapy of severe infections caused...
Analysis of antibacterial agents in clinical and preclinical development: overview and analysis 2025
The World Health Organization’s (WHO) “2025 Antibacterial agents in clinical and preclinical development: an overview and analysis” report...
Accelerating the development of priority formulations for antibiotic use in children : target product...
This document summarizes proceedings and outcomes of a technical consultation designed to develop target product profiles for three priority antibiotics...
Accelerating optimal approval of priority formulations for antibiotic use in children: meetings report,...
On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments...
Towards investigation, development and introduction of cefiderocol in children: product brief
Cefiderocol was included in WHO’s PADO priority list because of its efficacy against multiple pathogens in the WHO bacterial priority pathogens list,...
Related links
Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N
Lancet Respir Med. 2018;6(3):223-230
Review on Antimicrobial Resistance, May 2016, Chaired by Jim O'Neill